Its expanded presence in the Asia-Pacific region will strengthen its ability to support increasingly complex, global clinical trials
WIRB-Copernicus Group (WCG) Clinical Services Division, provider of solutions to improve the quality and efficiency of clinical research, has opened the company’s new office in Tokyo, Japan.
WCG’s expanded presence in the Asia-Pacific region will strengthen its ability to support increasingly complex, global clinical trials, particularly in the critical areas of drug and diagnostic development for oncology and central nervous system (CNS) diseases.
“WCG’s Tokyo office will be home to our Clinical Services Division in Asia, as well as a center of excellence for our growing Patient Engagement Group,” said Dr Donald A. Deieso, chairman and CEO of WCG.
“By expanding WCG’s footprint abroad, we are helping to ensure that every trial— especially the most complicated and challenging ones—can benefit from our latest advances in trial optimization, signal detection and patient recruitment.”
WCG maintains an active presence in 65 countries around the world, helping research sponsors, contract research organisations (CROs) and investigative sites to work together more effectively to conduct faster, safer and more predictable clinical trials.
In the past decade, Asia has become an increasingly attractive destination for clinical research, with a clinical trials infrastructure designed to foster speed, cost effectiveness and quality. With a population of more than four billion people, Asia also provides research sponsors with access to a large number of patients for clinical trial recruitment.